PERSPECTIVES

Latest post

November is Diabetic Eye Disease Awareness Month

This November, in support of Diabetic Eye Disease Awareness Month, Oxurion is partnering with Prevent Blindness and its sight saving efforts.

science community

“An aspiring name to reflect our focus and ambition”

“The new name comes from combining the words Oxygen and Orion”, explains CEO Patrik De Haes, MD. “Raising oxygen levels in cells plays a key role in helping prevent and reverse ...

eye community

“Cutting-edge research can change people’s lives”

“Partnerships with the industry and biotech companies like Oxurion are crucial to us,” says Jeff Todd, President & CEO of Prevent Blindness US. “It is vital that ...

back of the eye diseases, science community

“We need therapies fighting different hallmarks simultaneously”

PDR and DME are two manifestations of diabetic retinopathy (DR), and in many respects they stem from the same cause, explains Prof. Alan Stitt, Dean of Innovation & Impact and ...

eye community

“Join forces to fight eye disease in developing countries”

“In those parts of the world there are many patients who lack access to routine retinal care,” Dr. Agrawal explains. “We aim to provide clinical care by sending retina ...

back of the eye diseases, science community

“Developing novel drugs through collaboration and strong science”

“We work as a complimentary team, putting Oxurion in a unique position as a very agile biotech company,” says Susan Schneider, who joined the company’s leadership team in 2017 ...

oncology research

“Looking at the future of immuno-oncology therapy”

This past year Oncurious concluded an agreement with VIB to acquire exclusive licenses to a portfolio of five innovative immuno-oncology assets. Those unique new targets ...

eye community

“Training ophthalmologists to fight blindness in developing countries”

“Our key ambition is to put an end to avoidable blindness worldwide,” says Isabelle Verhaegen, Director of Light for the World. “Creating awareness of eye diseases really is ...

back of the eye diseases

“JETREA has a group of very loyal users worldwide”

Vinciane Vangeersdaele joined the Oxurion leadership team this past year. With extensive experience in commercializing pharmaceutical portfolios worldwide, including in ...

eye community

“Oxurion remains innovator in novel retinal therapies”

“There is currently an explosion in R&D activities in the retinal space. Numerous potential new therapies are ready for translation into clinical studies, making this a truly ...

oncology research

Fighting brain cancer in children

Medulloblastoma is the most common malignant brain tumor, accounting for 20% of all brain tumors in children. This very aggressive type of cancer affects mostly young children ...